Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M41,280Revenue (TTM) $M5,517Net Margin (%)23.2Altman Z-Score11.7
Enterprise Value $M40,604EPS (TTM) $11.0Operating Margin %34.2Piotroski F-Score4
P/E(ttm)34.9Beneish M-Score-2.4Pre-tax Margin (%)33.8Higher ROA y-yY
Price/Book6.810-y EBITDA Growth Rate %--Quick Ratio3.1Cash flow > EarningsN
Price/Sales8.15-y EBITDA Growth Rate %--Current Ratio3.6Lower Leverage y-yN
Price/Free Cash Flow55.5y-y EBITDA Growth Rate %56.0ROA % (ttm)16.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)25.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M107ROIC % (ttm)29.5Gross Margin Increase y-yY

Gurus Latest Trades with REGN

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

REGN is held by these investors:



REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BROWN MICHAEL SDirector 2017-10-05Sell1,500$475-18.17view
BAKER CHARLES ADirector 2017-09-29Sell2,000$450-13.62view
Landry Robert ESVP Finance & CFO 2017-09-06Sell663$498.6-22.04view
Landry Robert ESVP Finance & CFO 2017-08-31Sell427$493.43-21.22view
Sanofi10% Owner 2017-08-25Buy72,378$481.36-19.25view
Sanofi10% Owner 2017-08-24Buy166,415$480.93-19.18view
Landry Robert ESVP Finance & CFO 2017-08-23Sell468$476.45-18.42view
VAGELOS P ROYChairman of the Board 2017-08-22Sell56,213$474.48-18.08view
VAGELOS P ROYChairman of the Board 2017-08-18Sell15,191$470.15-17.32view
Landry Robert ESVP Finance & CFO 2017-08-08Sell526$472.19-17.68view

Quarterly/Annual Reports about REGN:

News about REGN:

Articles On GuruFocus.com
Regeneron Announces Upcoming Investor Conference Presentation Nov 15 2017 
US Stock Market Bearish Wednesday Nov 08 2017 
Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clin Nov 07 2017 
Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at th Nov 01 2017 
Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination w Nov 01 2017 
Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 S Oct 31 2017 
Regeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations Oct 27 2017 
Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time Oct 19 2017 
Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active M Oct 16 2017 
Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Oct 11 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK